Osimertinib for use in the treatment of non-small cell lung cancer
OwnerAnthony Francis Patrick NASHinventor
Life of this patent
Estimating the term…
Abstract
The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.
Claims14
-12. (canceled)
A method of treating locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non small cell lung cancer (NSCLC) in a human patient comprising administering to the patient osimertinib or a pharmaceutically acceptable salt thereof, wherein the EGFR mutation-positive NSCLC has not progressed following definitive platinum-based chemoradiation therapy.
(canceled)
Dependencies are inferred from the claim text.